Plato Investment Management Ltd Trims Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Plato Investment Management Ltd lowered its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 58.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 498 shares of the company’s stock after selling 688 shares during the quarter. Plato Investment Management Ltd’s holdings in Janux Therapeutics were worth $27,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. FMR LLC lifted its stake in Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after buying an additional 47,075 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after buying an additional 721,563 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after purchasing an additional 38,490 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Janux Therapeutics by 190.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock worth $17,985,000 after purchasing an additional 259,445 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Up 5.0 %

JANX stock opened at $31.50 on Thursday. Janux Therapeutics, Inc. has a 52 week low of $29.63 and a 52 week high of $71.71. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -26.92 and a beta of 3.16. The business has a fifty day simple moving average of $42.23 and a 200-day simple moving average of $47.67.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on JANX. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Stifel Nicolaus increased their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday. Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. Finally, Wedbush reissued an “outperform” rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $88.00.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $4,507,788.32. This represents a 13.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 50,002 shares of company stock worth $2,684,703. Corporate insiders own 29.40% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.